Studies Validate IL-17 as Hidradenitis Suppurativa Drug Target
Two phase 3 studies with the IL-17 inhibitor bimekizumab for moderate-to-severe hidradenitis suppurativa generate clinically meaningful results, researchers report.
Medscape Medical News
source https://www.medscape.com/viewarticle/989861?src=rss
Medscape Medical News
source https://www.medscape.com/viewarticle/989861?src=rss
Comments
Post a Comment